Clinical trials: sponsored by H. Lundbeck A/S
Healthy
A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects
The purpose of this study is to evaluate how well Lu AG09222 can prevent blood vessel dilation in a headache model.
- Trial name
- NCT04976309
- Testing
- Lu AG09222
- Where
- Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
Safety and Tolerability of Lu AG06479 in Healthy Young Men
The purpose of this study is to investigate the safety and tolerability of Lu AG06479 and what the body does to Lu AG06479 after swallowing single doses of the drug.
- Trial name
- NCT04473651
- Testing
- Lu AG06479
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy, Parkinson Disease
Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease
The purpose of this study is to investigate the safety of a single dose of Lu AF82422, how well it is tolerated, how the drug effects the body and what the body does to the drug in healthy non-Japanese and Japanese subjects and…
- Trial name
- NCT03611569
- Testing
- Lu AF82422
- Where
- 4 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects
The purpose of the study is to investigate how the body absorbs and get rid of eptinezumab when given directly into a vein in Chinese subjects.
- Trial name
- NCT05045781
- Testing
- Eptinezumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Migraine
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.
- Trial name
- RELIEF (NCT04152083)
- Testing
- Eptinezumab
- Where
- 57 sites in United States, Georgia
- Volunteers
- 485 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD
- Trial name
- NCT03108625
- Testing
- Vortioxetine
- Where
- 31 sites in Bulgaria, Estonia and 11 more
- Volunteers
- 94 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Real-life Effectiveness of Vortioxetine in Depression
Worldwide Major Depressive Disorder (MDD) has significant negative personal, societal and economic consequences. Vortioxetine (Brintellix®) is a new antidepressant authorized since 2013.
- Trial name
- RELIEVE (NCT03555136)
- Testing
- Vortioxetine
- Where
- 106 sites in United States, Canada and 2 more
- Volunteers
- 992 people
- Sponsor
- H. Lundbeck A/S
MDD, Anxiety Disorders
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression coexisting with generalized anxiety disorder.
- Trial name
- RECONNECT (NCT04220996)
- Testing
- Vortioxetine
- Where
- 21 sites in Estonia, France and 4 more
- Volunteers
- 100 people
- Sponsor
- H. Lundbeck A/S
Healthy
Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men
The purpose of this study is to evaluate the effect of repeated doses of the drug Lu AG06466 on the exposure of metoprolol, midazolam and bupropion
- Trial name
- NCT04713254
- Testing
- Lu AG06466, Midazolam, Metoprolol
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in the Brain
This study will investigate how much of Lu AF88434 will get into the blood and the brain in healthy men
- Trial name
- NCT04538014
- Testing
- Lu AF88434, [11C]-Lu AF88434
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Parkinson Disease
An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients
To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the Lu AE04621 and metabolite after ascending oral doses of Lu AE04621 in patients with Parkinson's Disease.
- Trial name
- NCT02649608
- Testing
- 0.04 mg Lu AE04621, 0.08 mg Lu AE04621, 0.2 mg Lu AE04621
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- H. Lundbeck A/S
Healthy
Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men
This study evaluates the effect of Lu AF88434 on the body and what the body does to Lu AF88434 and the effect of food after swallowing single oral doses
- Trial name
- NCT04082325
- Testing
- Lu AF88434, Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434), Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
- Where
- Netherlands
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
Binding of Lu AG06466 in the Brain in Healthy Men
A study to learn how Lu AG06466 and one of its break down products binds in the brain after single and repeated dosing
- Trial name
- NCT04419636
- Testing
- Lu AG06466
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy, Parkinson Disease
Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)
A study to learn how foliglurax binds in regions of the brain
- Trial name
- NCT04175132
- Testing
- foliglurax
- Where
- Sweden
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
To evaluate the safety and tolerability of the long-term treatment with Lu AF35700.
- Trial name
- Debut (NCT02892422)
- Testing
- Lu AF35700
- Where
- 102 sites in United States, Bulgaria and 11 more
- Volunteers
- 528 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms in patients with schizophrenia
- Trial name
- NCT03793712
- Testing
- Lu AF11167 (1-2 mg/day), Lu AF11167 (3-4 mg/day)
- Where
- 53 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 168 people
- Sponsor
- H. Lundbeck A/S
Migraine
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD1910, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
- Trial name
- NCT04197349
- Testing
- ALD1910, Sumatriptan
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
A study to evaluate the long-term safety and tolerability of flexible doses of Lu AF11167 in patients with schizophrenia during the 24-week treatment period
- Trial name
- NCT03929497
- Testing
- Lu AF11167
- Where
- 30 sites in Bulgaria, Estonia and 5 more
- Volunteers
- 96 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition)…
- Trial name
- NCT02709746
- Testing
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day
- Where
- 124 sites in United States, Bulgaria and 17 more
- Volunteers
- 784 people
- Sponsor
- H. Lundbeck A/S
Healthy
Eptinezumab in Healthy Japanese Subjects
The purpose of this study is to investigate how eptinezumab enters, moves through and exits the body. Safety and tolerability will also be investigated.
- Trial name
- NCT04336449
- Testing
- Eptinezumab
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S